(2,5-二甲基-1H-吲哚-3-基)乙酸 | 5435-40-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: (2,5-二甲基-1H-吲哚-3-基)乙酸
• 中文别名: (2,5-二甲基-1H-吲哚-3-基)-乙酸；2-(2,5-二甲基-1H-吲哚-3-基)乙酸
• 英文名称: (2,5-dimethyl-indol-3-yl)-acetic acid
• 英文别名: (2,5-Dimethyl-indol-3-yl)-essigsaeure；2-(2,5-dimethyl-1H-indol-3-yl)acetic acid；2-(2,5-dimethylindol-3-yl)acetic acid；2,5-Dimethyl-indol-3-essigsaeure；(2,5-dimethyl-1H-indol-3-yl)acetic acid
• CAS: 5435-40-5
• 化学式: C₁₂H₁₃NO₂
• mdl: MFCD02664400
• 分子量: 203.241
• InChiKey: TYNHPLJFWKDNTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (2,5-二甲基-1H-吲哚-3-基)乙酸 在 溶剂黄146 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 14.0h， 生成 methyl (Z)-4-(2,5-dimethyl-1H-indol-3-yl)-3-(phenylamino)but-2-enoate
  参考文献：
  名称：

  碘 (III) 介导的 C–C 键偶联构建不同环大小的螺环假吲哚

  摘要：

  在此，我们报告了一种新型的碘 (III) 介导的吲哚衍生物的分子内脱芳环化螺环化，以中等至良好的收率生成高度应变的螺环丁基、螺环戊基和螺环己基吲哚啉。在温和的反应条件下，以这种方式有效地构建了一组具有广泛官能团相容性的结构新颖、密集官能化的螺吲哚。此外，β-烯胺酯作为产品中的多功能官能团，为生物活性化合物及相关天然产物的合成提供了极大的便利。

  DOI：

  10.1021/acs.orglett.3c01106
• 作为产物：
  描述：

  4-p-tolylhydrazono-valeric acid 在 zinc(II) chloride 作用下， 生成 (2,5-二甲基-1H-吲哚-3-基)乙酸
  参考文献：
  名称：

  Koegl; Kostermans, Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1935, vol. 235, p. 201,213

  摘要：

  DOI：

文献信息

• INDOLE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1600440A1

  公开（公告）日：2005-11-30

  An indole derivative compound represented by formula (I) (wherein the symbols in the formula are as mentioned in the specification) and a salt thereof Since the compounds represented by formula (I) binds to PGD2 receptors and shows antagonistic activity, they are believed to be useful for prevention and/or treatment of diseases such as allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, systemic mast cell activating disorder, anaphylaxis shock, airway contraction, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis, urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleep disorder) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, autoimmune disease, chronic articular rheumatism, pleuritis, ulcerative colitis and irritable bowel syndrome.

  公式（I）所代表的吲哚衍生物化合物及其盐由于公式（I）所代表的化合物结合到PGD2受体并显示拮抗活性，因此认为它们对预防和/或治疗过敏疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身组织细胞增生症、全身组织细胞活化障碍、过敏性休克、气道收缩、荨麻疹、湿疹、伴有瘙痒的疾病（如特应性皮炎、荨麻疹）、由于伴有瘙痒行为（如搔抓和敲打）而次生产生的疾病（如白内障、视网膜脱离、炎症、感染和睡眠障碍）、炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、自身免疫疾病、慢性关节风湿病、胸膜炎、溃疡性结肠炎和肠易激综合征等疾病的预防和/或治疗可能是有用的。
• Hypoglycemic imidazoline compounds
  申请人：——

  公开号：US20040009976A1

  公开（公告）日：2004-01-15

  This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.

  这项发明涉及某些新型咪唑啉化合物及其类似物，它们用于治疗糖尿病、糖尿病并发症、代谢紊乱或相关疾病，其中存在葡萄糖代谢障碍，以及包含它们的药物组合物，以及它们的制备方法。
• Compounds exhibiting thrombopoietin-like activities
  申请人：——

  公开号：US20030162724A1

  公开（公告）日：2003-08-28

  The compounds of the invention are compounds represented by the following general formula (1): 1 wherein E represents one selected from the group consisting of a methylidyne group and a nitrilo group, R 1 represents one selected from the group consisting of optionally substituted aryl groups and optionally substituted heteroaryl groups, R 2 represents one selected from the group consisting of a hydrogen atom and alkyl groups, W 1 represents an amino acid residue, A represents one selected from the group consisting of a carbonyl group and a sulfonyl group, X 1 represents one selected from the group consisting of optionally substituted alkylene groups and optionally substituted alkenylene groups, and p represents 0 or 1; and their pharmacologically acceptable salts, which exhibit thrombopoietin-like activity.

  本发明的化合物是由以下一般式（1）表示的化合物：其中E代表从甲基亚基团和硝基亚基团组成的群体中选择的一种，R1代表从可选择的取代芳基和可选择的取代杂环烷基组成的群体中选择的一种，R2代表从氢原子和烷基组成的群体中选择的一种，W1代表氨基酸残基，A代表从羰基和磺酰基组成的群体中选择的一种，X1代表从可选择的取代烷基烯基团和可选择的取代烯基烷基团组成的群体中选择的一种，p代表0或1；以及它们的药理学上可接受的盐，具有类似于血小板生成素的活性。
• Indole derivative compounds and drugs containing the compounds as the active ingredient
  申请人：Iwahashi Maki

  公开号：US20060089353A1

  公开（公告）日：2006-04-27

  An indole derivative compound represented by formula (I) (wherein the symbols in the formula are as mentioned in the specification) and a salt thereof Since the compounds represented by formula (I) binds to PGD 2 receptors and shows antagonistic activity, they are believed to be useful for prevention and/or treatment of diseases such as allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, systemic mast cell activating disorder, anaphylaxis shock, airway contraction, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis, urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleep disorder) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, autoimmune disease, chronic articular rheumatism, pleuritis, ulcerative colitis and irritable bowel syndrome.

  一种印地安蓝衍生物化合物，其化学式表示为(I)（其中化学式中的符号如说明书中所述），以及其盐。由于化合物(I)与PGD2受体结合并表现出拮抗活性，因此它们被认为对预防和/或治疗过敏性疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身性肥大细胞病、全身性肥大细胞激活症、过敏性休克、气道收缩、荨麻疹、湿疹、伴有瘙痒的疾病（如特应性皮炎、荨麻疹）、由于瘙痒行为（如搔抓和敲打）而次生产生的炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、自身免疫性疾病、慢性关节风湿病、胸膜炎、溃疡性结肠炎和肠易激综合征等疾病有用。
• COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1291341A1

  公开（公告）日：2003-03-12

  The compounds of the invention are compounds represented by the following general formula (1): wherein E represents one selected from the group consisting of a methylidyne group and a nitrilo group, R1 represents one selected from the group consisting of optionally substituted aryl groups and optionally substituted heteroaryl groups, R2 represents one selected from the group consisting of a hydrogen atom and alkyl groups, W1 represents an amino acid residue, A represents one selected from the group consisting of a carbonyl group and a sulfonyl group, X1 represents one selected from the group consisting of optionally substituted alkylene groups and optionally substituted alkenylene groups, and p represents 0 or 1; and their pharmacologically acceptable salts, which exhibit thrombopoietin-like activity.

  本发明的化合物是由以下通式（1）表示的化合物： 其中 E 代表选自由甲炔基和亚硝基组成的组，R1 代表选自由取代芳基和选自由取代杂芳基组成的组，R2 代表选自由氢原子和烷基组成的组，W1 代表氨基酸残基，A 代表选自由羰基和磺酰基组成的组，X1 代表选自由取代亚烷基和选自由取代烯基组成的组，p 代表 0 或 1；及其药理上可接受的盐类，这些盐类具有类似血小板生成素的活性。